Clearly you continue to be the #$%$ Hole that we know you to be. I was completely self deprecating when writing what I wrote. Aside from that it is completely accurate and there is not a single point that is not accurate. I would guess that Fas will not be in disagreement . Now GFY
that is a good point. my self while I knew it would take time having waited 17 years on MEDX. I did not anticipate the number of mis-steps. I expected a gradual increase in the pps based on execution . I expected the company to be much further along in the process ,with more success to show for it. Marc now watching expenses as if CYTX was a start up was something that management should have been doing when it was. Not because of inefficient uses of capital. so I am a stuck holder until a couple weeks after June 10th when we will learn if we have been Calhouned. He has not left the building. Good luck to all.
meh, hendrik simply has to get the company to a point that they have some credibility. he strikes me as an honest and straight forward guy. his knowledge about the science is second to none. as things stand now the company is just not in a position to attract the ceo that they need who can monetize the value of the technology. barda if positive will go along way in giving validation to the company and the future. a partnership deal out of europe on sports medicine or any of the other studies where ce mark approval will allow the generation of substantial revenues would also go a long way in establishing credibility while improving the balance sheet and making Cytori a company that the right CEO would want to come to. I like the cost cutting, and wish they would cut guys like Clyde shores who have had more then enough time to do something positive, yet have failed miserably. and are draining funds from the company that surely could be spent in a more productive way. the greatest frustration has been that if something can go wrong it will and that many deals that were pending were not finalized for one reason or another. some good news sure would go a long way.
Hedge not going to trade insults with you not my intention. You have no idea of my buying patterns on Cytori nor should it be a concern ,of yours which I am certain it is not. You are who you are, your agenda is your agenda and is clear to all. again best of luck.
Hedge, I have come to learn from your posts that you have to be short Cytori and always have been. Kind of a wolfs in sheep"s clothing so to speak. You speak out of both sides of your mouth depending on the message board or who you are replying to. This is of course a public forum and you are free to do and act however, you want. I respect your knowledge by clearly you have your own agenda. Best of luck to you.
Cytori Therapeutics, Inc. Buy
(CYTX – NASDAQ – $2.37)
Reports the Quarter – Lowering PT from $10.00, to $9.00, based on adjustments to both current revenue and trial enrollment timelines. BARDA progress should be a positive event ahead.
Ø Cytori had revenues of just $1.4M, below our reduced expectations, against expenses of $10.5M. The company ended the quarter with $12.8M in cash and $3.6M in receivables. We also note that Cytori entered into a sales agreement with Cowen and Company, under which it may offer and sell shares of common stock having an aggregate offering price of up to $40M, an “ATM” facility.
Ø BARDA Set to Advance. Cytori and BARDA have scheduled an in-process review meeting on June 10, 2014, to consider expanded funding to Cytori under the contract. A favorable review from this meeting may lead to additional contract revenue for a U.S. clinical trial program in thermal burn injury.
Ø We remain focused on fundamentals, highlighted as follows:
o ATHENA is enrolling, now in 10 sites, and the first ATHENA II sites are open. Timelines are pushed back but are now realistic (two to four patients per month); ATHENA I fully enrolls at N=45 patients. Once fully enrolled, the plan will be to transition those sites to ATHENA II sites.
o Achieved all three planned contract milestones related to the BARDA contract, and a review meeting is now set for June 10, 2014. The outcome and funding could be transformative.
2014 Operating Goals
o Complete ATHENA enrollment (2014) and make substantial enrollment progress in ATHENA II (both trials have begun)
o Advance BARDA contract into the next phases, including a U.S. feasibility trial and expanded research and development
o Achieve approval for the Celution System in China
o Grow research product sales in existing and new markets through new partnerships and recent changes in Japanese regenerative medicine law
o Initiate additional “proof-of-concept” studies in additional indications based partly on investigator-sponsored data sets, such as hand manifestations associated with scleroderma
Ø Valuation. Basing the valuation on our assumptions in CMI, we expect 2020 EPS of $9.80, and discounting back at 30% yields a $9.00 price target.
don't count your chickens before they hatch. one thing is for sure and that is you can't believe anything you hear from Cytori management. I'll believe it when the check is in the bank. You seem to be an intelligent poster and new to Cytori unless this is just another ID you go under,having done your DD you should know this.
the filing is a renewal of existing shelf registration. not sure what the big deal is
The registrant has an existing “shelf” Registration Statement that was declared effective on May 9, 2011 and which expires on May 9, 2014, pursuant to Securities and Exchange Commission (the “SEC”) rules. Accordingly, the registrant is filing this new shelf Registration Statement for the purpose of continuing to provide the registrant with the ability to sell securities from time to time covered by this Registration Statement. The registrant has included in this Registration Statement ,397,246 of securities (the “Unsold Securities”) registered pursuant to Registration Statement No. 333-172787. Pursuant to Rule 415(a)(6) under the Securities Act, ,619 of filing fees previously paid in connection with the Unsold Securities will continue to be applied to the Unsold Securities. In accordance with SEC rules, the registrant may continue to offer and sell the Unsold Securities during the grace period afforded by Rule 415(a)(5). If the registrant sells any Unsold Securities during the grace period, the registrant will identity in a pre-effective amendment to this Registration Statement the new amount of Unsold Securities to be carried forward to this Registration Statement in reliance upon Rule 415(a)(6).
It is disgusting, disappointing, and a host of other not so kind expletives, but it is what it is. This is what you get when a company has zero credibility. Cytori usually announces some surprise the day before an earning call so we still have 2 more trading days for that. May warrants will expire worthless and I am surprised they are letting that happen. So much for any pop from Wall Streets seeking Alpha article but I do appreciate his efforts
definitely will not come out of meeting with answer. hendrick has made it clear that in the opinion of cytx management they have achieved the criteria. management has told us all along that they meet with fda and barda on a regular basis,therefore they must know the goals for each milestone.
they have put in writing that a major accomplishment for 2013 was to have achieved milestones, can guidance possibly be that bad? History aside,dare i say the odds may be tilted in out favor. (i bite my tongue)
I am thinking that perhaps Cytori released this information today to give the market a week to get the pps up so that options /warrants that expire on May 12th have a chance of being execised. They had to do something, perhaps something else to come that is tangible,other then BARDA which is a maybe.
They had to complete the meetings as it was a pre-requisite to set this review,according to what mangement explained to us during the last call.
Good to see communication with shareholders for the first time I can remember. This is surely the most important meeting Cytori will have , and is a make or break IMHO.
charlie a very similar article came out about 3 years ago raising same type of concerns more focus on leakage damage. We thought our ship had come in as Cytori had been telling us what focus they had on this. Nothing materialized, no reimbursement I think was the problem. It just seems we have all this promise and then just when we think this is , and then it is snatched away. Hope BARDA breaks the trend and our foutunes turn.
you got that right for sure cyt. it's pathetic go down one road, bump into a wall, go down another road, change direction, start again, going after breast construction, not going after breast reconstruction, aplications good for plastic surgery no wait it isn't. no wonder we sit here at $2.30 down from $8.50. Operating on the blind squirrel management theory is ineffective, expensive, and why nobody believes a dam thing this
management team tells us. Hope they gain some credibility on BARDA announcement which is supposed to come in 2nd quarter.
Mac, I notice that your position on Cytori is a strong sell. That seems odd, since you are receiving treatment that may save your life. Would you please explain why you have a strong cell opinion.
I just don't get the CYTORI decision making process and that they had to think about giving patients that received placebo treatment for free at later date. It just goes along with all the other poor decsions they make. They would rather be foolish and have difficulty fully enrolling trial and delay even more what is moving at a snails pace as it is. Par for the course. Better late then never I guess . We so need a competent CEO. Imagine how much further along we would be if we had one . They just continue to operate by trial and error,it sad just sad.